Taribavirin
File:Viramidine.png | |
Clinical data | |
---|---|
Synonyms | 1-(β-D-Ribofuranosyl)- 1,2,4-triazole-3-carboximide |
Pregnancy category |
|
Routes of administration | Oral capsule |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 9% |
Metabolism | Metabolized to 5'phosphates, de-riboside, and deriboside carboxylic acid |
Elimination half-life | 12 days - Multiple Dose; 120-170 hours - Single Dose |
Excretion | 10% fecal, remainder in urine (30% unchanged, remainder metabolites) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C8H13N5O4 |
Molar mass | 243.220 g/mol (279.681 g/mol for HCl salt) |
Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include hepatitis C and perhaps also hepatitis B and yellow fever.
Taribavirin is as active against influenza as ribavirin in animal models, with slightly less toxicity, so it may also eventually replace ribavirin as an anti-influenza agent.
Taribavirin is being developed by Valeant Pharmaceuticals International, the parent company of Ribapharm, the company which first reported synthesis and testing of the drug in 1973. Valeant is testing the drug as a treatment for chronic hepatitis C.
Note on formulas: The carboxamidine group of this molecule is somewhat basic, and therefore this drug is also known and administered as the hydrochloride salt (with a corresponding .HCl chemical formula and different ChemID / PubChem number). At physiologic pH, the positive charge on the molecule from partial protonation of the carboximide group contributes to the relative slowness with which the drug crosses cell membranes (such as in red blood cells) until it has been metabolized into ribavirin. In the liver, however, the transformation from carboxamidine to carboxamide happens on first-pass metabolism and contributes to the higher levels of ribavirin found in liver cells and bile when viramidine is administered.
References
- Barnard, D (2002). "Viramidine (Ribapharm)". Current Opinion in Investigational Drugs. 3 (11): 1585–9.
- Gish, Robert G. (2006). "Treating HCV with ribavirin analogues and ribavirin-like molecules". Journal of Antimicrobial Chemotherapy. 57 (1): 8–13. doi:10.1093/jac/dki405. PMID 16293677. Unknown parameter
|month=
ignored (help) - Lin, Chin-Chung (2003). "Pharmacokinetics and Metabolism of 14C Viramidine in Rats and Cynomolgus Monkeys". Antimicrob Agents Chemother. 47 (8): 458–2463. Unknown parameter
|coauthors=
ignored (help) - Sidwell, RW (2005). "In vitro and in vivo influenza virus-inhibitory effects of viramidine". Antiviral Research. 68 (1): 8–13. PMID 16087250. Unknown parameter
|coauthors=
ignored (help); Unknown parameter|month=
ignored (help) - Witkowski, J. T. (1973). "Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides". Journal of Medicinal Chemistry. 16: 935–7. Unknown parameter
|coauthors=
ignored (help)
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Pages with citations using unsupported parameters
- Antivirals
- Prodrugs
- Triazoles